Minetta C. Liu

Natera (United States)

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index62

i10-index162

Publications587

Citations18,898

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 153

Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Figure 8 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Figure 6 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Data from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
Supplementary Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026-06-17
45Prognostic Utility of ctDNA vs. Conventional Biomarkers in Resected Biliary Tract Cancer: A Real-World Analysis
The Oncologist · 2026-06-01
Tu1369 PERFORMANCE OF A BLOOD-BASED SCREENING TEST FOR THE EARLY DETECTION OF ADVANCED PRECANCEROUS LESIONS
Gastroenterology · 2026-05-01
Tu1369 PERFORMANCE OF A BLOOD-BASED SCREENING TEST FOR THE EARLY DETECTION OF ADVANCED PRECANCEROUS LESIONS
Gastrointestinal Endoscopy · 2026-05-01
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.
UNC Libraries · 2026-01-03

Open author page on OpenAlex →